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Abstract
Background: The traditional Japanese medicine juzentaihoto (JTX) is a pharmaceutical grade multi-herbal medicine
widely used for the prevention of cancer metastasis and infection in immuno-compromized patients in Japan. The
effect of JTX has been supposed to be intimately affected by the immunological properties of host and enteric
microflora. The influence of JTX on the gene expression profile in the large and small intestines was investigated
by microarray analyses using mice of different strains with or without enteric microflora.
Results: In all types of mice, including germfree (GF) animals, the genes most affected by two-week oral JTX
treatment were the type 1 interferon (IFN)-related genes including Stat1, Isgf3g and Irf7, which play a critical role in
the feedback loop of IFN-a production cascade. In IQI specific pathogen free (SPF) mice JTX increased the steady
state level of the expression of IFN-related genes, but had the opposite effect in IQI GF and BALB/c SPF mice.
Promoter analysis suggests that tandem repeated $IRFF (the promoter sequences for interferon regulatory factors)
may be a primary target for JTX action. Pre-treatment of JTX accelerated the effects of an oral IFN “inducer” 2-
amino-5-bromo-6-methyl-4-pyrimidinol (ABMP) (up-regulation of IFN-a production in IQI strain and down-
regulation in BALB/c mice), which is in good accordance with the effect of JTX on gene expression of type 1 IFN-
related genes.
Conclusions: Microarray analysis revealed that the target of JTX might be the transcription machinery regulating
the steady-state level of genes involved in the ISGF3-IRF7 cascade, whose effect is bi-directional in a strain- and
microbiota-dependent manner.
Background
In Japan, certain traditional herbal medicines (Kampo
medicines), which comprise hot water extracts from a
mixture of medicinal plants, have been widely used as
ethical drugs and become integrated into the modern
medical system [1-4]. These traditional medicines are
manufactured under strict scientific quality control and
are covered by public health insurance. A large amount
of clinical and basic research on Kampo medicines has
been performed, including more than 10 multicenter,
placebo-controlled, double-blind studies.
We investigated the effects of Juzentaihoto (JTX) in
this study. JTX is a well known Kampo medicine that
comprises 10 different herbs; Ginseng radix, Astragali
radix, Angelicae radix, Rehmanniae radix, Atractylodis
lanceae rhizoma, Cinnamomi cortex, Poria, Paeoniae
radix, Ligustici rhizoma and Glycyrrhizae radix. JTX has
been used for centuries for the treatment of various
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toid arthritis, atopic dermatitis, chronic fatigue syn-
drome and ulcerative colitis [5-12]. Experimental studies
show that JTX reduces the side effect of chemotherapy
and radiotherapy [13-17], prevents various types of can-
cer and its metastasis [18-24], improves osteoporosis
[25,26] as well as atopic dermatitis [1], and protects
against Candida infection [19,27]. The active substances
responsible for stimulation of hematopoietic stem cell
growth [28,29], various immunostimulating activities
[28,30-34], alleviation of side-effects by chemotherapeu-
tic agents [32,35], and protection against Candida infec-
tion [36] have been identified.
In Kampo therapy, medical care is individualized with
tailoring prescriptions depending on the patients’ consti-
tution, disease state and responsiveness to therapy
[2,37,38]. Indeed, the therapeutic effects of Kampo-med-
icines have been known to vary markedly among indivi-
duals. Therefore, depending on the individual patient it
is not unusual to use different Kampo drugs to treat the
same disease, or alternatively, to use the same drug to
treat apparently different diseases. Thus, the effect of
Kampo medicines should be investigated by taking into
consideration the possible dependence on the constitu-
tion, for example the immunological properties, of the
individual patient.
Most Kampo medicines administered orally are known
to have probiotic, prebiotic and antibiotic properties. For
example, we have previously demonstrated that JTX
alters the population of intestinal microflora, which
affects the gene expression of heat shock proteins hsp70
and hsp110 in the gut and liver (Kampo affects micro-
flora) [39]. Conversely, certain glycosides included in
Kampo medicines are known to require metabolic con-
version to a bioactive deglycosylated form by intestinal
flora for expression of their pharmacological activity
(Microflora affects Kampo) [2]. Finally, certain immuno-
modulating effects of Kampo medicines, including JTX,
are known to be mediated by chemical components that
are not thought to be absorbed [33,36,40]. The compo-
nents of Kampo medicines may affect general immunity
indirectly, presumably through interaction with the gut
local immune system. Thus, the intestinal microflora is
thought to play a critical role in eliciting the beneficial
effects of Kampo medicines.
Because each Kampo medicine contains a vast number
of ingredients, the biological effects are presumably
mediated by multiple active components and their var-
ious target sites of action. Thus, a study involving any
specific medicinal component or site of action is, in
principle, inadequate. To clarify the action of such a
complicated medicine requires an exhaustive approach
such as transcriptome or proteome analysis. However,
there have been very few studies that adopt an “omics”
approach aimed at studying the pharmacology of
Kampo medicines.
Here, we have attempted to resolve the above-men-
tioned problem by using the following approaches. 1)
We investigated the effect of JTX on gene expression in
the large intestines. As previously described, the effect
of JTX extends over various organs and the entire body.
However, the biological properties of JTX on the intes-
tines may involve a broad spectrum of pharmacological
effects. 2) We used GeneChip
® arrays to obtain a gen-
ome-wide profile of gene expression after JTX treat-
ment. 3) We compared enteric flora-present specific
pathogen-free (SPF) and enteric flora-absent Germ-free
(GF) mice of the IQI strain to evaluate the influence of
microflora on the action of JTX. 4) To determine the
effect of the difference of immune properties the same
experimental investigation was additionally performed
on SPF Balb/c mice. Our investigation has identified a
possible molecular pathway to explain the well-known
effect of JTX in reducing the incidence of viral infec-
tions. Specifically, JTX enhances interferon-a production
via elevation of steady-state expression level of inter-
feron regulatory factors such as Stat1, Stat2, Isgf3g and
Irf7.
Results
Literature analysis of GeneChip data
Firstly, we investigated the effect of JTX on the steady
state level of mRNA in the large intestines using IQI
specific pathogen free (SPF) and Balb/c SPF mice
(Experiment 1). When we applied the criteria described
in Materials and Methods (p < 0.1, fold change > 1.5 or
< 0.67), there were 27 and 16 annotated/identified genes
whose expression level was increased by JTX treatment
in IQI and Balb/c mice, respectively ("SPFLI-up” and
“BALBLI-up” lists in Table 1 and Additional File 1,
respectively). The numbers of down-regulated genes
were 13 and 22 in IQI and Balb/c mice, respectively
("SPFLI-down” and “BALBLI-down” lists in Additional
File 2 and Table 2 respectively). There were no common
denominations between the up-regulated genes in IQI
and those in Balb/c, and between the down-regulated
genes in IQI and those in Balb/c. However, there was a
striking commonality (8 genes, about 30% of listed
genes) in the panels of genes that were up-regulated in
IQI and genes down-regulated in Balb/c mice (bold let-
ters in “SPFLI-up” and “BALBLI-down” lists, Tables 1
and 2). To elucidate the transcriptional co-regulation
n e t w o r k st r i g g e r e db yJ T X ,w eu s e dG e n o m a t i x ’ Biblio-
sphere software, which allows analyzing gene/gene, and
gene/transcription factor relations from their co-citation
in PubMed abstracts. The above gene lists were used as
input to Bibliosphere. This approach allowed us to
reveal relationships between the cluster of JTX-affected
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co-cited with all or some of the genes from the input
cluster, with the information as to whether these genes
have certain promoter sequences. The results of this
type of analysis, termed Cluster Centered BiblioSphere,
are shown in Figure 1. Eleven (IQI) and 9 (Balb/c) genes
are presented in Figure 1 and they have all been
reported to be induced by type 1 interferon (other input
genes were found to have no co-citation and therefore
not presented in the figure) [41]. In particular, transcrip-
tion factors Isgf3g and Irf7 are known to play a defini-
tive role in the proximal sector in the signaling
pathways mediating massive interferon-a production
[42]. Accordingly, 6 of 8 genes that are common
between the “SPFLI-up” and “BALBLI-down” lists con-
tain promoter sequences for Irf7 or Isgf3g. Additionally,
we analyzed the effect of JTX on the expression profile
of the small intestine of IQI SPF mice. The profiles of
the small intestine were completely different from, and
had scarce commonality with, those of the large
intestine of IQI SPF mice (Table 1 and Additional File
2, 3, 4).
Next we analyzed the GeneChip results of large and
small intestines of IQI germ-free (GF) mice. In the large
intestine, 13 genes have been listed as up-regulated
("GFLI-up” list in Additional File 5). Genes down-regu-
lated by JTX treatment include 24 immunoglobulins.
The “GFLI-down” list in Table 3 shows the other 31
annotated/identified genes. Seven (Irf7, Isgf3g, Ifit1, Ifit2,
Iigp2, Rsad2 and Lgals9) of the 31 genes are common to
those up-regulated in IQI SPF mice (i.e., “SPFLI-up” list
in Table 1) and are known to be induced by type 1
interferons. The list of genes whose expression is signifi-
cantly down-regulated in GF mice small intestines com-
prise 42 genes ("GFSI-down” list in Table 4). Unlike the
results from SPF mice, the “GFSI-down” list (Table 4)
shows a striking commonality with the “GFLI-down” list
(15 of 31 genes, Table 3) and “SPFLI-up” list (9 of 27
g e n e s ,T a b l e1 ) .T h eB i b l i o s p h e r ea n a l y s i sg a v eC l u s t e r
Centered Bibliosphere figures consisting of 23 out of 31
Table 1 The upward effect of JTX on the gene expression in the large intestine in IQI SPF mice
SPFLI-up
Probe Set ID Gene Name Gene Symbol Entre ID Fold Change p-value
93956_at interferon-induced protein with tetratricopeptide repeats 3 Ifit3 15959 4.71 0.092
95024_at ubiquitin specific peptidase 18 Usp18 24110 4.50 0.020
98822_at ISG15 ubiquitin-like modifier G1p2 53606 4.06 0.077
100981_at interferon-induced protein with tetratricopeptide repeats 1 Ifit1 15957 3.84 0.033
103066_at thymidylate kinase family LPS-inducible member Tyki 22169 3.72 0.012
103639_at interferon-induced protein with tetratricopeptide repeats 2 Ifit2 15958 3.37 0.036
104669_at interferon regulatory factor 7 Irf7 54123 2.87 0.069
98410_at interferon inducible GTPase 2 Iigp2 54396 2.49 0.021
104177_at radical S-adenosyl methionine domain containing 2 Rsad2 58185 2.45 0.033
103335_at lectin, galactose binding, soluble 9 Lgals9 16859 2.40 0.038
93442_at zinc finger protein 316 Zfp316 54201 1.97 0.065
161357_r_at glutathione S-transferase, mu 2 Gstm2 14863 1.90 0.049
102867_at TEA domain family member 4 Tead4 21679 1.82 0.009
100909_at protease, serine, 8 (prostasin) Prss8 76560 1.81 0.066
103657_i_at metal response element binding transcription factor 2 Mtf2 17765 1.73 0.081
102879_s_at Fc receptor, IgG, high affinity I Fcgr1 14129 1.71 0.053
92560_g_at vascular cell adhesion molecule 1 Vcam1 22329 1.69 0.036
95037_at cyclin-dependent kinase 9 (CDC2-related kinase) Cdk9 107951 1.69 0.086
104708_at Transducin (beta)-like 1 X-linked Tbl1x 21372 1.67 0.082
103884_at ATP binding domain 1 family, member C Atpbd1c 68080 1.66 0.061
99446_at membrane-spanning 4-domains, subfamily A, member 1 Ms4a1 12482 1.63 0.083
103634_at interferon dependent positive acting transcription factor 3 gamma Isgf3g 16391 1.58 0.068
93464_at A kinase (PRKA) anchor protein (yotiao) 9 Akap9 100986 1.54 0.088
92384_at xeroderma pigmentosum, complementation group A Xpa 22590 1.54 0.051
100472_at enabled homolog (Drosophila) Enah 13800 1.52 0.067
103080_at SAM domain and HD domain, 1 Samhd1 56045 1.51 0.045
102808_at Sodium channel, voltage-gated, type I, beta Scn1b 20266 1.51 0.074
The genes whose change was > 1.50 fold, with p < 0.1 (n = 3, Welch’s t test) were the listed sorted by fold-change. Unidentified 8 probe sets were omitted from
the list. The genes appeared commonly in Tables 1 and 2 were in bold letters.
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genes from “GFSI-down” list (Figure 3) that have been
co-cited in PubMED abstracts. Figures 2 and 3 both
include the two transcription factors, Isgf3g and Stat1,
which are known to be located upstream of the Isgf3g-
Irf7 signaling pathway. The contents of tables and sup-
plementary tables are summarized in Additional File 6.
Collectively, these data strongly suggest that JTX influ-
ences, at least in part, the signaling pathways of inter-
feron-a production in the large intestines of different
mice strains (IQI or Balb/c) and different microflora sta-
t u s( S P Fo rG F ) .T h e s ec o n c l u s i o n sa l s oa p p l yt ot h e
small intestines of GF animals. The composite of Cluster
Centered Bibliosphere figures of “BALB-down”, “SPFLI-
up”, “GFLI-down” and “GFSI-down” figures are shown
in Figure 4 suggesting almost all genes affected by JTX
are under the regulation of either Stat1, Isgf3g or Irf7.
Validation by quantitative real time RT-PCR
To confirm the results of GeneChip data, quantitative
real time RT-PCR analysis has been performed on 26
genes, focusing on type 1 interferon-related genes. As
shown in Table 5, many of the changes in interferon-
related genes shown in GeneChip data have been con-
firmed by PCR. Messenger RNAs of IFN-b,I F N - a2a n d
IFN-a4, the end-products of signaling pathways of type
1 interferon production, were under the detection limit
of real time PCR and unaffected by JTX treatment.
These findings are in good agreement with the results
of GeneChip analyses.
Promoter analysis of GeneChip data
Genes, whose expression profiles changed according to
the GeneChip and PCR data analysis, were further
investigated. Several of these genes were found to act on
the signaling pathway map of type 1 interferon produc-
tion. The effect of JTX appeared to focus on the neigh-
borhood of the ISGF3 signaling pathway (Figure 5). To
investigate the transcription regulation working behind
the change of gene transcription, we performed promo-
ter sequence analysis using Genomatix’ ElDorado/Gen-
e2Promoter/FrameWorker system to find transcription
factor motifs in similarly regulated genes. Co-regulation
of mammalian genes usually depends on sets of tran-
scription factors rather than an individual factor alone.
Regulatory sequence elements are often organized into
defined frameworks of motifs of two or more transcrip-
tion factor binding sites and clusters of such motifs. The
FrameWorker software combined with the genome
annotation database/interface ElDorado/Gene2Promoter
Table 2 The downward effect of JTX on the gene expression in the large intestine in Balb/c SPF mice
BALBLI-down
Probe Set ID Gene Name Gene Symbol Entre ID Fold Change p-value
160841_at D site albumin promoter binding protein Dbp 13170 0.27 0.029201
104177_at radical S-adenosyl methionine domain containing 2 Rsad2 58185 0.39 0.012171
95024_at ubiquitin specific peptidase 18 Usp18 24110 0.41 0.016077
160933_at interferon gamma induced GTPase Igtp 16145 0.46 0.052323
100981_at interferon-induced protein with tetratricopeptide repeats 1 Ifit1 15957 0.48 0.030177
98822_at ISG15 ubiquitin-like modifier G1p2 53606 0.49 0.053022
103202_at guanylate nucleotide binding protein 4 Gbp4 55932 0.52 0.018878
98410_at interferon inducible GTPase 2 Iigp2 54396 0.55 0.008083
93956_at interferon-induced protein with tetratricopeptide repeats 3 Ifit3 15959 0.56 0.053353
103634_at interferon dependent positive acting transcription factor 3 gamma Isgf3g 16391 0.56 0.009681
101561_at metallothionein 2 Mt2 17750 0.59 0.001359
93573_at metallothionein 1 Mt1 17748 0.61 0.00141
161964_r_at Protein kinase C, zeta Prkcz 18762 0.61 0.066851
103335_at lectin, galactose binding, soluble 9 Lgals9 16859 0.62 0.024207
99076_at Nuclear receptor subfamily 1, group D, member 2 Nr1d2 353187 0.63 0.049119
93085_at proteosome (prosome, macropain) subunit, beta type 9 Psmb9 16912 0.63 0.00915
160208_at splicing factor 3b, subunit 3 Sf3b3 101943 0.63 0.043591
104750_at interferon gamma inducible protein 47 Ifi47 15953 0.64 0.053488
161287_f_at MYB binding protein (P160) 1a Mybbp1a 18432 0.64 0.014332
93178_at neuronal guanine nucleotide exchange factor Ngef 53972 0.65 0.017146
92315_at schlafen 4 Slfn4 20558 0.65 0.053414
104669_at interferon regulatory factor 7 Irf7 54123 0.67 0.017792
The genes whose change was < 0.67 fold, with p < 0.1 (n = 3, Welch’s t test) were the listed sorted by fold-change. Unidentified 4 probe sets were omitted from
the list “BALBLI-down”, respectively. The genes appeared commonly in Tables 1 and 2 were in bold letters.
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promoter region of the input genes. Twelve genes that
w e r ec o m m o n l yi d e n t i f i e di nm o r et h a n3l i s t so f
“BALB-down”, “SPFLI-up”, “GFLI-down” and “GFSI-
down” (see Figure 5) were analyzed. Twenty models
have been found as the operable modules consisting of
two transcription factors. Four models with the lowest
FW-scores (V$IRFF-V$IRFF, 1.43974e-05; V$IRFF-V
$MYT1, 1.73886e-05; V$CREB-V$GCMF, 1.7771e-05; V
$ETSF-V$DEAF, 5.56327e-05) were subjected to further
examination. The appearance ratio of each model in the
genes affected by JTX treatment and in the all annotated
mouse promoters are shown in Table 6. The average
and SD of the ratio of four cases (SPFLI-up, BALB-
down, GFLI-down, and GFSI-down) was statistically
compared and significant differences were found for V
$IRFF-V$IRFF, V$IRFF-V$MYT1 and V$CREB-V
$GCMF. The location of V$IRFF-V$IRFF in JTX-
affected genes is illustrated in Figure 6.
JTX enhanced the ABMP-induced increase of IFN-alpha
production in the large intestine of IQI SPF mice
To investigate whether the difference of basal expression
levels of the IFN-related genes results in the altered pro-
duction of IFN-a, we examined the effect of IFN-indu-
cer on production of IFN-a protein in the large
Figure 1 Cluster Centered BiblioSphere for listed genes and co-cited transcription factors/genes. The genes up-regulated in IQI SPF
mouse large intestine (A) and the genes down-regulated in BALB/c mouse large intestine (B) are shown. A line indicates that the genes at both
ends are co-cited in specific abstract(s) of PUBMED. A thick line with gray scale indicates that the gene at the dark end regulates expression of
the genes at the lighter end i.e., transcription factor located upstream of the genes. A thick line in solid black indicates that the genes at both
ends regulate the expression of each other. Genes with no co-citation have been omitted from the diagram. Orange, the genes whose fold
change > 2; yellow, the genes whose fold change < 2; light blue, the genes whose fold change < 0.67.
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effect of three oral IFN-a inducers, 2-Amino-5-bromo-
6-methyl-4-pyrimidinol (ABMP), tilorone analog
R11567DA and imiquimod. Oral administration of 30
mg/kg body weight of Imiquimod, a TLR7 agonist,
rapidly (2 hr) increased the IFN-a protein level of
serum but not that of the intestines. Oral administration
of 100 mg/kg body weight of R11567DA increased the
level of IFN-a in both the serum and intestines within 4
hr. The increase in IFN-a level in the intestines induced
by ABMP took place over a prolonged period of time
(30 hr) and was relatively modest. However, ABMP did
not induce IFN-a production in the serum. Therefore
ABMP was thought to be suitable for evaluation of the
net increase of intestinal IFN-a production. Hence, in
the following experiments we chose to use ABMP. The
effects of ABMP at the doses of 250, 500, 1000 mg/kg
body weight have been compared and 250 mg/kg was
determined as the suitable dosage (data not shown).
As shown in Figure 7, in the absence of stimulation by
ABMP, the level of IFN-a p r o t e i ni nt h el a r g ei n t e s t i n e
was unaffected by a two week administration of JTX in
IQI mice. However, in accordance with the GeneChip
data, expression levels of Stat1, Stat2 and Irf7 were
increased. When ABMP was administered in JTX-trea-
ted mice, maximum concentration of IFN-a protein
Table 3 The downward effect of JTX on the gene expression in the large intestine in IQI GF mice
GFLI-down
Probe Set
ID
Gene Name Gene
Symbol
Entre
ID
Fold
Change
p-
value
103842_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked Ddx3y 26900 0.02 0.004
103674_f_at eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked Eif2s3y 26908 0.07 0.008
103639_at interferon-induced protein with tetratricopeptide repeats 2 Ifit2 15958 0.09 0.015
104750_at interferon gamma inducible protein 47 Ifi47 15953 0.12 0.002
100981_at interferon-induced protein with tetratricopeptide repeats 1 Ifit1 15957 0.18 0.021
104177_at radical S-adenosyl methionine domain containing 2 Rsad2 58185 0.20 0.012
102906_at T-cell specific GTPase Tgtp 21822 0.24 0.034
96764_at interferon inducible GTPase 1 Iigp1 60440 0.27 0.001
103202_at guanylate nucleotide binding protein 4 Gbp4 55932 0.29 0.045
160933_at interferon gamma induced GTPase Igtp 16145 0.30 0.004
98410_at interferon inducible GTPase 2 Iigp2 54396 0.36 0.014
104669_at interferon regulatory factor 7 Irf7 54123 0.38 0.034
103335_at lectin, galactose binding, soluble 9 Lgals9 16859 0.38 0.039
100030_at uridine phosphorylase 1 Upp1 22271 0.40 0.015
103634_at interferon dependent positive acting transcription factor 3 gamma Isgf3g 16391 0.44 0.040
92715_at ubiquitin D Ubd 24108 0.44 0.011
93085_at proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional
peptidase 2)
Psmb9 16912 0.47 0.036
102791_at proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional
peptidase 7)
Psmb8 16913 0.49 0.014
103446_at interferon induced with helicase C domain 1 Ifih1 71586 0.50 0.038
101465_at Signal transducer and activator of transcription 1 Stat1 20846 0.51 0.026
103035_at transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) Tap1 21354 0.54 0.035
97950_at xanthine dehydrogenase Xdh 22436 0.54 0.010
104597_at guanylate nucleotide binding protein 2 Gbp2 14469 0.56 0.025
97507_at lectin, galactoside-binding, soluble, 3 binding protein Lgals3bp 19039 0.60 0.047
102200_at aquaporin 8 Aqp8 11833 0.60 0.019
102873_at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) Tap2 21355 0.60 0.015
103254_at TRAF type zinc finger domain containing 1 Trafd1 231712 0.60 0.011
103892_r_at elongation factor RNA polymerase II 2 Ell2 192657 0.62 0.039
99475_at suppressor of cytokine signaling 2 Socs2 216233 0.66 0.024
92672_at GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus Gnas 14683 0.67 0.010
98472_at histocompatibility 2, T region locus 23///RIKEN cDNA C920025E04 gene H2-T23 15040 0.67 0.007
The genes whose change was < 0.67 fold and with p < 0.1 (n = 3, Welch’s t test) were the listed sorted by fold-change. Twenty four immunoglobulin genes and
14 unidentified probe sets were omitted from the lists. The genes appeared commonly in both Tables 3 and 4 were in bold letters. The genes appeared
commonly in Tables 1 and 3 were underlined.
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ever, IFN-a release peaked much earlier in mice given
ABMP compared with the control mice. Furthermore,
JTX treatment increased the peak level of Stat1, Stat2
and Irf7 mRNAs.
Similar experiments using the same protocol were per-
formed on another strain of Balb/c mice (Figure 8). IFN-
a protein levels in the large intestine were unaffected by
a two week administration of JTX alone. However, in
accordance with GeneChip data, the steady-state levels
Table 4 The downward effect of JTX on the gene expression in the small intestine in IQI GF mice
GFSI-down
Probe Set ID Gene Name Gene Symbol Entre ID Fold Change p-value
103842_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked Ddx3y 26900 0.01 0.006
103674_f_at eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked Eif2s3y 26908 0.03 0.022
95024_at ubiquitin specific peptidase 18 Usp18 24110 0.11 0.003
100981_at interferon-induced protein with tetratricopeptide repeats 1 Ifit1 15957 0.15 0.010
93956_at interferon-induced protein with tetratricopeptide repeats 3 Ifit3 15959 0.17 0.009
160933_at interferon gamma induced GTPase Igtp 16145 0.19 0.000
98822_at ISG15 ubiquitin-like modifier G1p2 53606 0.20 0.035
92718_at interferon, alpha-inducible protein 27 Ifi27 76933 0.24 0.019
104750_at interferon gamma inducible protein 47 Ifi47 15953 0.25 0.009
98030_at tripartite motif protein 30 Trim30 20128 0.25 0.003
104177_at radical S-adenosyl methionine domain containing 2 Rsad2 58185 0.27 0.004
102906_at T-cell specific GTPase Tgtp 21822 0.29 0.000
92472_f_at schlafen 2 Slfn2 20556 0.31 0.004
98410_at interferon inducible GTPase 2 Iigp2 54396 0.32 0.007
103066_at thymidylate kinase family LPS-inducible member Tyki 22169 0.36 0.024
97409_at immunity-related GTPase family, M Irgm 15944 0.36 0.021
103446_at interferon induced with helicase C domain 1 Ifih1 71586 0.39 0.010
102699_at myxovirus (influenza virus) resistance 2 Mx2 17858 0.42 0.012
93078_at lymphocyte antigen 6 complex, locus A Ly6a 110454 0.43 0.030
160668_at opioid growth factor receptor Ogfr 72075 0.44 0.006
103254_at TRAF type zinc finger domain containing 1 Trafd1 231712 0.44 0.043
103202_at guanylate nucleotide binding protein 4 Gbp4 55932 0.44 0.013
101465_at signal transducer and activator of transcription 1 Stat1 20846 0.44 0.021
103634_at interferon dependent positive acting transcription factor 3 gamma Isgf3g 16391 0.47 0.006
103035_at transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) Tap1 21354 0.48 0.027
103080_at SAM domain and HD domain, 1 Samhd1 56045 0.50 0.016
103812_at chloride channel calcium activated 1 Clca1 12722 0.50 0.019
160847_at tRNA nucleotidyl transferase, CCA-adding, 1 Trnt1 70047 0.52 0.014
102873_at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) Tap2 21355 0.57 0.037
100475_at tripartite motif protein 25 Trim25 217069 0.58 0.025
98283_at 5’-3’ exoribonuclease 1 Xrn1 24127 0.61 0.005
96151_at Molybdenum cofactor sulfurase Mocos 68591 0.61 0.010
102812_i_at ubiquitin-activating enzyme E1-domain containing 1 Ube1dc1 66663 0.62 0.003
94461_at pre-B-cell colony-enhancing factor 1 Pbef1 59027 0.62 0.030
95886_g_at CREB binding protein Crebbp 12914 0.63 0.012
103673_at complement component 2 (within H-2S) C2 12263 0.63 0.013
97921_at Agrin Agrn 11603 0.63 0.043
102279_at ubiquitin-activating enzyme E1-like Ube1l 74153 0.64 0.013
104070_at p300/CBP-associated factor Pcaf 18519 0.64 0.002
96157_at zinc finger protein 91 Zfp91 109910 0.65 0.009
94192_at ganglioside-induced differentiation-associated-protein 10 Gdap10 14546 0.66 0.049
103025_at Moloney leukemia virus 10 Mov10 17454 0.67 0.042
The genes whose change was < 0.67 fold and with p < 0.1 (n = 3, Welch’s t test) were the listed sorted by fold-change. Eight immunoglobulin genes and 14
unidentified probe sets were omitted from the lists. The genes appeared commonly in both Tables 3 and 4 were in bold letters. The genes appeared commonly
in Tables 1 and 4 were underlined.
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Page 7 of 19of Stat1, Stat2 and Isgf3g decreased in JTX-treated mice.
To our surprise, administration of an “oral IFN inducer”
ABMP resulted in a significant decrease in IFN-a
release after 12 hr. The mRNA expression of Stat1,
Stat2 and Isgf3g was induced by ABMP, but the Irf7
mRNA level showed no change. JTX treatment did not
affect the basal level of IFN-a release, although the
decrease in the level of IFN-a was evident after only 8
hr in JTX-treated mice i.e., earlier than the control. JTX
decreased the level of Isgf3g and Irf7 mRNAs compared
to the control.
Discussion
Application of comparative functional genomics to phar-
macology may make it possible to classify the biological
effects of a certain drug into common universal effects
and host-specific and/or anecdotal effects. Such a strat-
egy is particularly useful for investigating the pharma-
cology of drugs with composite properties, such as
combination drugs, phytomedicines and traditional med-
icines that use relatively crude ingredients. This is
because these medicines generally have multiple active
components through which they target several different
molecules to exert their pharmacological efficacy. In the
present study, we performed transcriptome analyses to
profile the effect of a Kampo (Japanese traditional her-
bal) medicine, JTX. Different mice strains, whose immu-
nological properties have been reported to be
distinctive, were used. Furthermore, to classify the
microflora-dependent and -independent effect of JTX,
we used GF and SPF mice of the same IQI strain. Our
results have identified genes commonly affected by JTX
treatment across the different strains/status of mice,
which presumably represent the principal biological
effects of this Kampo medicine. However, the effects by
JTX on expression of these genes were directionally dif-
ferent among the strains/status (i.e., down-regulated in
BALB/c and IQI GF mice, up-regulated in IQI SPF
mice). Our data suggests the following conclusions: 1)
JTX has common target molecule(s), which may affect
the expression of type-1 IFN-related genes, such as Ifit1,
Stat1 and Irf7; 2) the active principles of JTX responsi-
ble for this phenomenon do not require the metabolic
conversion by intestinal microflora because the same
Figure 2 Cluster Centered BiblioSphere for listed genes and co-cited transcription factors/genes. The genes down-regulated in IQI GF
mouse large intestine are presented. A line indicates that the genes at both ends are co-cited in specific abstract(s) of PUBMED. A thick line
with gray scale gradation indicates that the gene at the dark end regulates expression of the genes at the lighter end i.e., transcription factor
located upstream of the genes. A thick line in solid black indicates that the genes at both ends regulate the expression of each other. Genes
with no co-citation have been omitted from the diagram. Light blue, genes whose fold change < 0.67. V$IRFF: genes having the promoter
sequences for interferon regulatory factors, V$STAT: genes having the promoter sequences for signal transducers and activators of transcription
genes. See website of Genomatix Inc http://www.genomatix.de/ for further information.
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functions of these molecules may be quite different
depending on the host strain/status. This is a plausible
explanation because the genes commonly affected by
JTX are the immune-related genes whose outcomes are
known to be drastically different (sometimes opposite)
depending on the strains [43] and the presence/absence
of intestinal microflora [44]. Furthermore, this finding
appears to be in good accordance with the concept that
Kampo medicines should be administered according to
the “Sho”. “Sho” is a principle of Kampo medicine that
recognizes the physical constitution, immunological pre-
disposition and responsiveness to the drugs can vary
between individual patients [7]. The precise interpreta-
tion of “Sho” in terms of modern medical science is yet
to be fully defined. Nonetheless, “Sho” is thought to be
intimately related to the patient’s immunological respon-
siveness and the state of intestinal microflora. Similarly,
we have demonstrated shosaikoto, another Kampo med-
icine, to have different, possibly even opposite, effects
on lung immunity in hosts with different genetic back-
grounds [45,46].
Interestingly, the genes affected by JTX were dissimilar
between the small and large intestine of SPF mice while
the genes affected by JTX have a lot of commonality
between these tissues in GF mice. As described in the
RESULTS section, the “GFSI-down” list (comprising 42
genes) share 15 genes with the “GFLI-down” list (com-
prising 31 genes) and 9 genes with the “SPFLI-up” list
(comprising 27 genes), respectively, while both the
“SPFSI-up” list (Additional File 3) and “SPFSI-down” list
(Additional File 4) share no genes with any other “up/
down” lists of “GFSI” (Additional File 7 and Table 4),
“GFLI” (Additional File 5 and Table 3) and even “SPFLI”
(Table 1 and Additional File 2). Thus, our results sug-
gest that the small intestine of SPF mice differentiate
via a distinct process. The “SPFSI” list includes many
metabolic enzymes. This suggests an extensive and large
scale alteration of the metabolic system in the SPF small
intestine. It has been reported that inoculation of bac-
teria into GF mice resulted in profound changes in
xenobiotic metabolism [47]. An extensive alteration of
small intestinal brush border enzymes between GF and
ex-GF piglets has also been noted [48]. Furthermore, a
Figure 3 Cluster Centered BiblioSphere for the listed genes and co-cited transcription factors/genes.T h eg e n e sd o w n - r e g u l a t e di nI Q I
GF mouse small intestine are presented. A line indicates that the genes at both ends are co-cited in specific abstract(s) of PUBMED. A thick line
with gray scale gradation indicates that the gene at the dark end regulates expression of the genes at the lighter end as the transcription factor.
A thick line in solid black indicates that the genes at both ends regulate the expression of each other. The genes with no co-citation have been
omitted from the diagram. Light blue, genes whose fold change < 0.67. V$IRFF: genes having the promoter sequences for interferon regulatory
factors, V$STAT: genes having the promoter sequences for signal transducers and activators of transcription genes. See website of Genomatix Inc
http://www.genomatix.de/ for further information.
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between the immune system, the intestinal metabolism
and the microbiota [49,50].
In this study, in both IQI and BALB/c strains, a similar
panel of IFN-related genes was affected by JTX treatment.
The panels include genes involved in signal pathway of
IFN-ainduction/production, such as Stat1, Isgf3g and Irf7,
and genes known as “IFN-stimulated genes”, which are
closely related to IFN-ainduction/production, such as
Ifit1, G1p2 (also known as ISG15), Igtp, Ifi47, Tgtp, Lgals9
and Rsad2 [41]. These findings have addressed the possibi-
lity that JTX may exert its pharmacological effect via mod-
ulating the signaling pathway for IFN production. In
particular, Irf7, is a rate limiting transcription factor
located in the center of a self-amplifying positive feedback
loop of massive IFN-a production [42]. Microbial infec-
tion induces phosphorylation of IRF7 protein, which is
then transported into nuclei to strongly induce the expres-
sion of IFN-as and Irf7 itself. In the presence of a kinase
activated by infectious agents, newly synthesized IRF7 con-
tinues to activate the loop resulting in a massive produc-
tion of IFN-as. The inducibility of IFN-a production in
various tissues/cells and their steady state level of IRF7
proteins are known to be closely correlated [51]. Isgf3g
(Irf9) and Stat1 are two components of ISGF3, a signaling
complex that transduces the signal from receptors of IFN-
a/b and induces the expression of IFN-a-related mole-
cules, including G1p2, Stat1 and Irf7 [52]. By contrast, the
expression of other interferon regulatory factors, such as
Irf1, Irf2 and Irf8, did not change. Indeed, the end-pro-
ducts of the pathway, such as the IFN-as, a2a n da4, were
undetectable. These data suggest that JTX treatment by
itself does not affect IFN-a expression directly. However,
the steady-state expression level of genes responsible for
induction of IFN-a synthesis are altered by JTX. Thus,
once the stimulatory signals are triggered, JTX-treated
mice produce altered levels of IFN-a protein. This conclu-
sion has been confirmed by the experiments using an oral
interferon inducer, ABMP. Although pretreatment by JTX
did not change the maximum level of IFN-a, the drug did
accelerate ABMP-induced changes in the production of
IFN-a protein.
In the early phase of infectious diseases, the prompt
supply of amounts of IFN-a protein effectively
Figure 4 A composite of Cluster Centered BiblioSphere of Figures 1, 2 and 3. A line indicates that the genes at both ends are co-cited in
specific abstract(s) of PUBMED. A thick line with gray scale gradation indicates that the gene at the dark end regulates the expression of genes
at the lighter end i.e., as a transcription factor. A thick line in solid black indicates that the genes at both ends regulate the expression of each
other. Genes with no co-citation have been omitted from the diagram. Violet, genes presented in all of 4 panels of Figures 1A, 1B, 2 and 3;
salmon pink, genes presented in 3 of 4 panels; bright pink, genes presented in 2 of 4 panels; white, genes presented in 1 of 4 panels. V$IRFF:
genes having the promoter sequences for interferon regulatory factors, V$STAT: genes having the promoter sequences for signal transducers and
activators of transcription genes. See website of Genomatix Inc http://www.genomatix.de/ for further information.
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Page 10 of 19eliminates viruses and prevents the dissemination of the
infectious agents into the whole body. Intriguingly,
another Kampo medicine, hochuekkito (HET) has been
reported to reduce the lethality due to influenza infec-
tion not by increasing the total (or peak) amount of
IFN-a but by accelerating the onset of IFN-a release in
the lung [53]. It is not known whether the acceleration
of IFN-a response by HET is mediated via transcrip-
tional up-regulation of the genes involved in IFN-a pro-
d u c t i o n ,i . e . ,S t a t 1 ,I s g f 3o rI r f 7 .I ti sa l s ou n c l e a r
whether JTX accelerates infection-triggered IFN-a pro-
duction or indeed whether the JTX-induced preventive
effects against infectious diseases are related to its accel-
eration of IFN synthesis signaling. In spite of the appar-
ent similarities between HET and JTX, beneficial effects
of these drugs have been suggested to have different
characteristics and responder patients, both clinically
and experimentally [13,54]. The comparative investiga-
tion of effects of both drugs on viral infection and IFN-
a production/degradation signaling pathways is now in
progress in our laboratory.
JTX by itself does not increase nor decrease IFN-a
production. Furthermore, the results of JTX treatment
were different among strains/enteric flora status.
Steady-state levels of IFN-related genes were up-regu-
lated in IQI SPF mice but down-regulated in IQI GF
and BALB/c mice. A stimulation by ABMP also
exerted opposite effects on IFN-a levels between IQI
SPF and BALB/c mice suggesting an additional, strain-
specific regulatory pathway(s) may exist upstream of
the ISGF3 complex. It is yet to be determined whether
the down-regulation of IFN-a responses by JTX is
Table 5 Verification of the changes in gene expression by quantitative realtime RT-PCR
Gene Name Gene Symbol Gene ID Effect of JTX (Fold
Change)*
RT-PCR
SPF GF primer/probe ID
Interferon-reguratory factors
interferon regulatory factor 1 (IRF1) Irf1 16362 1.18 1.00 Mm00515191_m1
interferon regulatory factor 3 (IRF3) Irf3 54131 1.00 1.18 Mm00516779_m1
interferon regulatory factor 5 (IRF5) Irf5 27056 3.79 1.46 Mm00496477_m1
interferon regulatory factor 6 (IRF6) Irf6 54139 1.09 1.35 Mm00516797_m1
interferon regulatory factor 7 (IRF7) Irf7 54123 2.81 0.33 Mm00516788_m1
interferon dependent positive acting transcription factor 3 gamma(IRF9) Isgf3g 16391 1.99 0.73 Mm00492679_m1
interferon consensus sequence binding protein 1(IRF8) Irf8 15900 1.00 1.40 Mm00492567_m1
Interferon-inducible genes
interferon-induced protein with tetratricopeptide repeats 1 Ifit1 15957 4.67 0.30 Mm00515153_m1
interferon-induced protein with tetratricopeptide repeats 2 Ifit2 15958 3.79 0.29 Mm00492606_m1
glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) Ifit3 15959 6.13 0.27 Mm01704846_s1
guanylate nucleotide binding protein 2 (mGBP-2) Gbp2 14469 1.10 1.03 Mm00494575_m1
ISG15 ubiquitin-like modifier G1p2 53606 6.00 0.23 Mm01705338_s1
chemokine (C-X-C motif) ligand 10 (IP-10) Cxcl10 15945 2.46 0.45 Mm00445235_m1
interferon inducible protein 1 (Ifi1) Irgm 15944 4.54 0.94 Mm00492596_m1
lectin, galactose binding, soluble 9 Lgals9 16859 2.53 0.58 Mm00495295_m1
interferon gamma induced GTPase Igtp 16145 2.37 0.42 Mm00497611_m1
lymphocyte antigen 6 complex, locus A (Ly6E.1, etc.) Ly6a 110454 2.25 0.39 Mm00726565_s1
2’-5’ oligoadenylate synthetase 1A Oas1a 246730 3.00 NT Mm00836412_m1
protein kinase, interferon inducible double stranded RNA dependent Prkr 19106 2.02 NT Mm00440966_m1
SAM domain and HD domain, 1 (Mgl1) Samhd1 56045 1.25 1.62 Mm00490121_m1
Type I interferon receptors
interferon (alpha and beta) receptor 1 Ifnar1 15975 1.04 1.60 Mm00439544_m1
interferon (alpha and beta) receptor 2 Ifnar2 15976 0.97 1.44 Mm00494916_m1
Type 1 interferons
MuIFN-alpha-2 interferon-alpha-2 gene Ifna2 15965 ND NT Mm00833961_s1
Interferon alpha family, gene 4 Ifna4 15967 ND NT Mm00833969_s1
Stat family
Signal transducer and activator of transcription 1(Stat1) Stat1 20846 2.96 NT Mm00439518_m1
Signal transducer and activator of transcription 2(Stat2) Stat2 20847 4.24 NT Mm00490880_m1
* Fold changes statistically significant (P < 0.05) are indicted in bold letter. NT: not tested.
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Page 11 of 19involved in the clinical effects of JTX. As well as play-
ing a critical role in defense against viral infections,
type I IFN also has a pivotal role at the interface
between innate and adaptive immunity. In spite of the
marked efficacy of recombinant IFN-a therapy, the
cytokine has been reported to be involved in the devel-
opment or exacerbation of numerous autoimmune
phenomena, including a variety of neuropathy
syndromes, neuromuscular junction disorders and
myopathies [55-57]. JTX displays various immunomo-
dulating activities [28,29,31,33,34,58-64]. These effects
should be investigated in thes c o p eo fac o m p l e xi n t e r -
play of many genetic and environmental factors that
influence the balance between normal and aberrant
immune responsiveness. The elucidation of mechanism
(s) of action by which JTX (and, presumably, ABMP)
Figure 5 Diagram of the signaling cascade of IFN-a production and a possible target for the action of JTX.
Table 6 Putative promoter modules affected by JTX treatment
module # module matches (# sequences) Appearance ratio (# matches/# sequences) Significance
SPFLI-up
(26)
BALB
-down (26)
GFLI
-down
(45)
GFSI
down (55)
All promoters
(51460)
SPFLI-up/BALB-down/GFLI-
down/GFSI-down*
All annotated
promoters
V$IRFF-V
$IRFF
31 33 55 67 19374 1.225 ± 0.032 0.376 < 0.0001
V$IRFF-V
$MYT1
14 12 24 30 13423 0.520 ± 0.039 0.261 0.0009
V$CREB-V
$GCMF
4 6 10 14 4675 0.215 ± 0.043 0.091 0.0104
V$ETSF-V
$DEAF
3 8 17 17 6540 0.277 ± 0.113 0.127 0.0706
* The values represent the mean ± S.D. of the appearance ration of these 4 groups.
Definition of promoter modules**
V$IRFF: interferon regulatory fatctors,
V$MYT1: MYT1 C2HC zinc finger protein,
V$CREB: cAMP-responsive element binding proteins,
V$GCMF: Chorion-specific transcription factors with a GCM DNA binding domain,
V$ETSF: Ets1 factors,
V$DEAF: Homolog to deformed epidermal autoregulatory factor-1 from D. melanogaster
**See Website of Genomatix Inc http://www.genomatix.de/ for further information.
Munakata et al. BMC Genomics 2012, 13:30
http://www.biomedcentral.com/1471-2164/13/30
Page 12 of 19exerts its influence on IFN-a synthesis/degradation
may lead to the elucidation of a novel regulatory path-
way of IFN-a regulation. Furthermore, the identifica-
tion of the target cell population of JTX may
contribute to the discovery of a novel type of IFN-a
producing cells. We [41] and other researchers [65]
have found that colonic IFN-a producing cells may be
distinct from authentic plasmacytoid dendritic cells,
the well-known IFN-a producer.
Conclusion
In the present study, by applying microarray analysis to
different strains/status of mice, we have tried to eluci-
date an essential component of the pharmacological
effect of JTX. Our results reveal that JTX modulates the
potency of IFN-a production by affecting the genes
related to the ISGF3 complex-IRF7 loop, rate-limiting
transcription factors involved in the IFN-a production
signaling pathway. We are currently attempting to iden-
tify the active ingredients of JTX and elucidate their
respective mechanisms of action.
Methods
Animals
Male IQI/Jic mice from CIEA (Kanagawa, Japan) and
BALB/c mice from Charles River Japan (Yokohama,
Japan Inc.) were kept under specific pathogen-free (SPF)
conditions. Germ-free (GF) mice were housed in a
Figure 6 The location of V$IRFF-V$IRFF cassettes in JTX-affected genes.
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free state and screened on a weekly basis for germ-free
status by sampling feces sterilely and culturing on MRS-
agar plates under aerobic and anaerobic conditions.
A l lm i c eu s e di nt h i ss t u d yw e r e7 - 9w e e k so l d .M i c e
were housed in an air-conditioned room (temperature 24
± 1°C) with a controlled light/dark cycle (light on between
6:30 AM and 7:00 PM). Food and water were available ad
libitum. The mice were randomly divided into two groups;
three to six mice were included in each group. One group
was orally treated with JTX solution (1.0 g/kg body
weight) and the other was treated with an equal volume of
water as control. JTX was administrated using a stainless
steel gastric tube once a day for 14 days. All animal proce-
dures were approved by the institution’s ethical committee
for care and use of laboratory animals in research.
Drugs
JTX, consisting of spray-dried hot water extracts of a
mixture of ten medicinal plants, was obtained from Tsu-
mura & Co. (Tokyo, Japan). The mixture consisted of
Astragali radix (3.0 g), Cinnamomi cortex (3.0 g),
Rehmanniae radix (3.0 g), Paeoniae radix (3.0 g), Ligus-
tici Rhizoma (3.0 g), Cnidii rhizoma, Atractylodis lan-
ceae rhizome (3.0 g), Angelicae radix (3.0 g), Ginseng
radix (3.0 g), Poria (3.0 g) and Glycyrrhizae radix (3.0
g). The origins and species of herbs, the contents of
characteristic and active ingredients and other pharma-
ceutical-grade qualities of JTX have been strictly con-
trolled as the ethical drug approved by the Ministry of
Health, Welfare and Labor of Japan. ABMP (2-Amino-
5-bromo-6-methyl-4-pyrimidinol), an oral interferon
inducer [66-68], was obtained from ACROS ORGANICS
(Fair Lawn, NJ).
Experiment 1
GF and SPF male IQI mice and SPF male BALB/c mice
(7 weeks old, n = 6 for each group) were orally treated
with JTX solution (0.1 g/ml/100 g body weight) or
water daily for 14 days. Whole portions of the small and
large intestine were homogenized and an aliquot of each
homogenate was subjected to total RNA extraction.
Labeled cRNA prepared from 3 mice per group was
hybridized to the GeneChip Murine Genome U74A V.2
Figure 7 ABMP-induced change in IFN-a production in the large intestine of IQI SPF mice after administration of either water (open
circle) or JTX (closed square). a: Amount of IFN-a protein. The release of IFN-a began earlier in JTX-treated mice than in the control mice. b-e:
Gene expression of Stat1, Stat2, Isgf3g, which compose an ISGF3 complex, and Irf7. The peak amount of all mRNA expression of Stat2 and Irf7
increased in JTX-treated mice. *p < 0.05. JTX-treated vs. control.
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Page 14 of 19(Affymetrix). Real time RT-PCR was used to confirm the
results of the GeneChip analysis using total RNA pre-
pared from the other 3 mice (per group).
Experiment 2
SPF male IQI and BALB/c mice (7 weeks old) were orally
treated with JTX solution (0.1 g/ml/10 g body weight) or
water daily for 2 weeks. Then an oral IFN inducer,
ABMP (2-Amino-5-bromo-6-methyl-4-pyrimidinol) was
administered once. ABMP was dissolved in water to
become 250 mg/kg and vortexed. At various times the
large intestines were taken, rinsed in phosphate-buffered
saline (PBS), and cut longitudinally. One half was used
for gene expression analysis and the other half for IFN-a
ELISA. Both samples were flash-frozen in liquid nitrogen
and stored at -80°C until use.
Obtaining of tissue samples
ABMP was administered and the large intestines were
obtained at various times. The tissue was rinsed in
phosphate-buffered saline (PBS) and cut longitudinally.
One half was used for gene expression analysis and the
other half for IFN-a ELISA. Both samples were flash-
frozen in liquid nitrogen and stored at -80°C until use.
RNA extraction from mice tissue
Mice were sacrificed and the large intestine taken for pre-
paration of total RNA. Each frozen sample was homoge-
nized in a 1 ml/0.1 g tissue of TRI REAGENT (Sigma-
Aldrich Japan, Tokyo, Japan) with a POLYTRON tissue
homogenizer (Kinematica, Littau-Lucerne, Switzerland)
and incubated for 10 minutes at RT. Chloroform (0.2 ml/1
ml TRI REAGENT) was added to the samples and the sus-
pensions were centrifuged at 13,200×g for 15 min at 4°C.
The water phase was transferred to a new tube and the
RNA prepared with a conventional isopropanol/ethanol
precipitate technique. To check the quality and quantity of
RNA, UV absorbance at 260 nm was determined and the
samples were also electrophoresed and visualized under
UV illumination after staining with ethidium bromide.
Microarray Analysis
Total RNA was extracted from mice (n = 3 per each
group) using TRIzol (Life Technologies, Rockville, TX)
Figure 8 ABMP-induced change in IFN-a production in the large intestine of Balb/c mice treated with water (open circle) or JTX (closed
square). a: Amount of IFN-a protein. The decrease of IFN-a began earlier in JTX-treated mice than in the control mice. b-e: Gene expression of
Stat1, Stat2, Isgf3g, and Irf7. The level of Isgf3g and Irf7 mRNAs was lower than the control at JTX-treated mice.
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Page 15 of 19and re-purified by RNeasy spin columns (Qiagen, Valen-
cia, CA) according to the manufacturer’si n s t r u c t i o n s .
All samples were monitored using an Agilent Bioanaly-
zer (Agilent Biotechnologies, Boeblingen, Germany) and
consistently demonstrated high-quality RNA (28S/18S
ratio, ~2). The labeled cRNA prepared by in vitro tran-
scription (Enzo Biochem, New York, NY) was fragmen-
ted, hybridized to a MG-U74Av2 array (Affymetrix,
Santa Clara, CA) using an Affymetrix fluidics station,
and scanned with an Affymetrix scanner, according to
the Affymetrix protocol. The array contains 12488
probe sets. Data were deposited to Gene Expression
Omnibus [69] and available under the series IDs:
GSE8006, GSE32083 and GSE32084. Data were analyzed
using the Affymetrix Microarray Suite (MAS) v.5.0 with
all of the parameters set at default values (a global nor-
malization was applied). The probe sets that had 2 or 3
absent A MAS detection calls per group (3 samples) in
all groups were excluded. Therefore, genes that had
more than 2 present calls in any one of the groups were
included in the analysis. Further, probe sets with signal
intensities less than 50 were omitted because prelimin-
ary evaluation by RT-PCR revealed poor reproducibility
for genes with lower signal intensities. Statistical ana-
lyses were performed by Welch’s t-test. This procedure
have been used in a series of our project including our
previous papers [39,41] and we have found that the cri-
teria of p < 0.1 is usable for obtaining data which is
worth additional validation experiments providing we
use the same protocols and that the animals are sourced
from the same provider (Central Institute for Experi-
mental Animals, Kanagawa, Japan). Some portions of
the microarray data are represented as heat maps in
Additional File 8.
Promoter analysis
Analysis of the sequences for transcription factor bind-
ing sites was conducted with the program MatInspector
Professional (Genomatix Software, Munich, Germany)
based on the MatInspector program using the selected
matrix library (vertebrate section) and optimized thresh-
olds. The promoter modules generated were compared
with the database using ElDorado software.
Reverse Transcription
Total RNA was extracted in a modified acid guanidium
thiocyanate-phenol-chloroform (AGPC) protocol by the
method mentioned above. The cDNA samples were
s y n t h e s i z e db yI m p r o m - I I T MR e v e r s eT r a n s c r i p t a s ek i t
(Promega Corporation, Madison, Wl) according to the
manufacturer’s instructions. Briefly, 5 ml of RNA and
primer were added to 15 ml reverse transcription reac-
tion mix (prepared by combining the following compo-
nents of the Improm-IITM Reverse Transcriptase
system). Annealing was performed by placing the tubes
in a controlled-temperature heat block equilibrated at
25°C and incubated for 5 minutes. Extension was per-
formed in a controlled-temperature heat block at 42°C
for up to one hour. The extension temperature was
optimized between 37°C and 55°C.
Real-time PCR
Real time RT-PCR was performed in two laboratory sites
where different PCR methodologies were used: the Taq-
Man
® Gold RT-PCR Kit without controls (Applied Bio-
systems, Foster City, CA), and the QuantiFast™ SYBR
Green PCR kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. These two assays gave
essentially the same results. For TaqMan
® assay, combi-
nations of probes and primers of Table 5 were used. Real
time PCR analysis was performed using an ABI Prism
7900 HT (Applied Biosystems) with the following ther-
mal cycling conditions: 1 cycle at 50°C for 2 min, 1 cycle
at 95°C for 10 min, followed by 40 cycles at 95°C for 15
sec and 60°C for 1 min. All samples were run in tripli-
cate. Data was normalized against Irf1. The cDNA tem-
plates were quantified by the QuantiFast™ SYBR Green
PCR kit according to the manufacturer’s instructions.
The sequences of the primers are shown in Table 7. Real
time PCR reactions were carried out with 50 ng of total
cDNA. The cycle parameters used were initial activation
step at 95°C 5 min, denaturing at 95°C for 10 seconds,
combined annealing and extension at 60°C for 30 sec-
onds. After amplification, samples were kept at 55°C for
1m i n u t ea n dt h et e m p e r a t u r ew a sr a i s e dg r a d u a l l yb y
0.5°C in every 10 seconds to perform the melt-curve ana-
lysis. All procedures for real time PCR were performed
on the iCycler iQTM Real-Time PCR Detection System
(Bio-Rad Laboratories, Tokyo, Japan) using the software
of this instrument. All measurements were performed in
triplicate. The threshold cycles (Ct) were used to quantify
the mRNA expression levels of samples with GAPDH
normalization. Some portions of the RT-PCR data are
represented as heat maps in Additional File 8.
Table 7 The primer sequences used for SYBR Green RT-
PCR
Specificty Primer pair Product size (bp)
Stat 1 5’-CACGCTGCCTATGATGTCTC-3’
5’-ACGCTTGCTTTTCCGTATGT-3’
132
Stat2 5’-CTTGTTCTTGGGTGGAGCACC-3’
5’-TTGGTGTAGGGCTGCACTGAG-3’
67
Isgf3g 5’-CATAGTTGGCACATGTGAGACA-3’
5’-ATCTCTCCAGCCGCTCTTAG-3’
121
Irf7 5’-CCCATCTTCGACTTCAGCAC-3’
5’-TGTAGTGTGGTGACCCTTGC-3’
88
Ifn-a 5’-GAATGCAACCCTCCTAGAC-3’
5’-GTCAGAGGAGGTTCCTG-3’
105
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Page 16 of 19Induction and quantitation of IFN-a protein
The frozen tissue was weighed, transferred to different
tubes on ice, and homogenized in the proportion of 100 mg
of the frozen tissue to 50 ml of PBS containing Complete
Mini Protease Inhibitor Cocktail tablets (Roche Diagnostics;
Indianapolis, IN) at a proportion of 1 tablet/10 ml at 4°C.
The large intestine homogenates were centrifuged at 55 g
for 30 seconds at 4°C through the gauze filter. The superna-
tant was then centrifuged at 2000 g for 3 minutes at 4°C.
Supernatants were transferred to 5.0 mm filter tubes
(MILLIPORE Corporation; Bedford, MA), centrifuged at
2000 g for 3 minutes at 4°C. IFN-a protein concentrations
in the large intestine tissue homogenates were determined
using an IFN-a Mouse ELISA kit (PBL Biomedical Labora-
tories; Piscataway NJ). Undiluted large intestine tissue
homogenates were applied in duplicate to the ELISA plate.
Statistical analyses
All data are expressed as the mean value ± S.E. Differ-
ences among groups were analyzed by Student’st - t e s t
and Fisher’s least significant test, and p < 0.05 was con-
sidered significant for RT-PCR and ELISA experiments.
Statistics for microarray analysis are described in the
relevant Methods section and Results section.
Additional material
Additional file 1: The upward effect of JTX on the gene expression
in the large intestine in BALB/c SPF mice.
Additional file 2: The downward effect of JTX on the gene
expression in the large intestine in IQI SPF mice.
Additional file 3: The upward effect of JTX on the gene expression
in the small intestine in IQI SPF mice.
Additional file 4: The downward effect of JTX on the gene
expression in the small intestine in IQI SPF mice.
Additional file 5: The upward effect of JTX on the gene expression
in the large intestine in IQI GF mice.
Additional file 6: Summary of altered gene lists.
Additional file 7: The upward effect of JTX on the gene expression
in the small intestine in IQI GF mice.
Additional file 8: Heat maps for gene expression data. (a) Gene chip
data of all the probe sets whose MAS calls are “present” for all triplicate
samples (a) and RT-PCR data of selected genes (b) were log-transformed
and subjected to heat map generation.
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